The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results